



## 22S-Butyl-1 $\alpha$ ,24R-dihydroxyvitamin D<sub>3</sub>: Recovery of vitamin D receptor agonistic activity<sup>☆</sup>

Yuka Inaba<sup>a,b</sup>, Makoto Nakabayashi<sup>b</sup>, Toshimasa Itoh<sup>a</sup>, Nobuko Yoshimoto<sup>a</sup>, Teikichi Ikura<sup>b</sup>, Nobutoshi Ito<sup>b</sup>, Masato Shimizu<sup>b</sup>, Keiko Yamamoto<sup>a,\*</sup>

<sup>a</sup> Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan

<sup>b</sup> School of Biomedical Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan

### ARTICLE INFO

#### Article history:

Received 13 October 2009

Received in revised form 12 February 2010

Accepted 25 February 2010

#### Keywords:

X-ray crystallography

Coactivator

Nuclear receptor

Hydrophobic interaction

Antagonist

### ABSTRACT

We recently reported that 22S-butyl-1 $\alpha$ ,24R-dihydroxyvitamin D<sub>3</sub> **3** recovers the agonistic activity for vitamin D receptor (VDR), although its 25,26,27-trinor analog **2** is a potent VDR antagonist. To investigate the structural features involved in the recovery of agonism, we crystallized the ternary complex of VDR–ligand-binding domain, ligand **3** and coactivator peptide, and conducted X-ray crystallographic analysis of the complex. Compared with the complex with **2**, the complex with **3** recovered the following structural features: a pincer-type hydrogen bond between the 24-hydroxyl group and VDR, the conformation of Leu305, the positioning of His301 and His393, the stability of the complex, and intimate hydrophobic interactions between the ligand and helix 12. In addition, we evaluated the potency of both compounds for recruiting RXR and coactivator. The results indicate that the complex with **3** generates a suitable surface for coactivator recruitment. These studies suggest that the action of **2** as an antagonist is caused by the generation of a surface not suitable for coactivator recruitment due to the lack of hydrophobic interactions with helix 12 as well as insufficient hydrogen bond formation between the 24-hydroxyl group and VDR. We concluded that the action of **3** as an agonist is based on the elimination of these structural defects in the complex with **2**.

© 2010 Elsevier Ltd. All rights reserved.

### 1. Introduction

Most biological actions of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>) **1** are mediated through the actions of its nuclear receptor (vitamin D receptor, VDR) [1]. Upon ligand binding, VDR undergoes a conformational change that promotes RXR–VDR heterodimerization, recruitment of coactivator, and initiation of transcription.

We have investigated the mechanism of biological actions of both VDR agonists and antagonists [2–4], and recently reported that 22S-butyl-25,26,27-trinor-1 $\alpha$ ,24-dihydroxyvitamin D<sub>3</sub> **2**, a synthetic vitamin D<sub>3</sub> analog, is a potent VDR antagonist [5]. Compound **2** possesses a unique side chain where terminus three carbons are removed while 22S-butyl group is added. X-ray crystallographic analysis of the ligand-binding domain (LBD) of VDR complexed with **2** demonstrated that **2** induces the formation of an extra cavity in the binding site to accommodate the 22S-butyl group, and eliminates the hydrophobic interactions between the side chain terminus and helix 12 of VDR–LBD. Moras's group reported the

same cavity, observed in zebrafish VDR–LBD/GEMINI complex [6,7]. It is interesting that GEMINI and compound **2** induce a common and characteristic cavity to accommodate the second side chain, but GEMINI works as a VDR agonist whereas **2** works as a VDR antagonist. These results imply that the antagonistic activity of compound **2** is related to decreased interactions with helix 12 [5,8]. We also found that 22S-butyl-1 $\alpha$ ,24R-dihydroxyvitamin D<sub>3</sub> **3**, which contains the three carbons absent from the side chain of **2**, showed the agonistic activity, albeit weakly [5]. We speculated that the agonistic activity of **3** is due to restored hydrophobic interactions with helix 12. To investigate the structural features responsible for the recovery of agonism of compound **3**, we crystallized the VDR–LBD/**3**/peptide complex and conducted X-ray crystallographic analysis. We also evaluated the potency of compounds **2** and **3** in recruiting RXR and coactivator (Scheme 1).

### 2. Materials and methods


#### 2.1. Crystallization and X-ray analysis

Crystallization and X-ray crystallographic analysis of the VDR–LBD/**3**/peptide complex was conducted as reported previously [5]. Briefly, the rat VDR–LBD (residues 116–423,  $\Delta$ 165–211) was over-

<sup>☆</sup> Special issue selected article from the 14th Vitamin D Workshop held at Brugge, Belgium on October 4–8, 2009.

\* Corresponding author. Tel.: +81 42 721 1580; fax: +81 42 721 1580.

E-mail address: [yamamoto@ac.shoyaku.ac.jp](mailto:yamamoto@ac.shoyaku.ac.jp) (K. Yamamoto).



Scheme 1.

produced as an N-terminal His<sub>6</sub>-tagged fusion protein in *Escherichia coli* C41. Affinity chromatography on a Ni-NTA column, tag removal by thrombin digestion, and gel filtration on a Superdex200 column, yielded purified rVDR-LBD protein. The VDR-LBD/3/peptide complex was crystallized by the vapor diffusion method. Diffraction data sets were collected at 100 K in a stream of nitrogen gas at beamline BL-6A of KEK-PF (Tsukuba, Japan). The structure of the complex was solved by molecular replacement with the program CNS [9] using a rat VDR-LBD coordinates (PDB code: 1RK3) [10]. The coordinates of the complex will be deposited in the Protein Data Bank with accession number 3AFR.

## 2.2. RXR and SRC-1 recruitment

Recruitment of RXR $\alpha$  and SRC-1 to VDR by 22S-butyl compounds (**2** and **3**) and 1,25-(OH)<sub>2</sub>D<sub>3</sub> (**1**) were assessed using HEK293 cells. The activities were evaluated by a dual luciferase assay [11] using VP16-VDR expression plasmid (pCMX-VP16-hVDR), RXR $\alpha$  or SRC-1 expression plasmid (GAL4-RXR $\alpha$  or GAL4-SRC-1), a reporter plasmid containing four copies of GAL4 response element (MH100x4-TK-Luc), and the internal control plasmid containing sea pansy luciferase expression construct (pRL-CMV). All experiments were carried out in triplicate.

## 3. Results and discussion

In contrast to the poor quality of the VDR-LBD/2/peptide complex (3.0 Å resolution) [5], the quality of the VDR-LBD/3/peptide complex was much better (2.0 Å resolution, Table 1). A ribbon-

tube representation of the rVDR-LBD/3/peptide complex is shown in Fig. 1c, and the rVDR-LBD/1/peptide and rVDR-LBD/2/peptide complexes are shown in Fig. 1a and b. The overall structure of the VDR-LBD complexed with **3** is similar to those complexed with **1** and **2**. The coactivator peptide is tightly bound to the activation function 2 (AF2) surface and occupies the typical agonist position (Fig. 1c). The crystal structure demonstrated that an additional cavity is produced in the same region observed in the rVDR-LBD/2/peptide complex, although the cavity is smaller (Fig. 1f). This cavity is formed because the terminus of the 22-butyl group of **3** pushes the Leu305 side chain away to rearrange the ligand-binding pocket (LBP) (Fig. 1k).

Ligand **3** was accommodated into the VDR-LBP in a manner similar to compounds **1** and **2**. The hydroxyl groups at the 1 $\alpha$ - and 3 $\beta$ -positions form pincer-type hydrogen bonds, evident in the VDR-LBD/1/peptide complex (Fig. 1j). Additionally, the 24-hydroxyl group forms hydrogen bonds with His393 and His301 (Fig. 1j). It should be noted that, in the complex with antagonist **2**, the 24-hydroxyl group formed a hydrogen bond with His393 but not with His301 [5]. Fig. 1k and l are superpositions of the complexes with **1**, **2** and **3**. As shown in Fig. 1l, His393 in the complex with **3** is shifted compared with the complex with **1** but His301 is not, whereas both His393 and His301 are shifted in the complex with **2**. The B-factors for the C $\alpha$  of His393 and His301 in the complex with **2**, but not with **1** and **3**, are rather larger than those of other unrelated residues (see PDB code: 3AFR). These results indicate that the complex with **3** recovered the almost correct hydrogen bond network composed of His393, His301 and the side chain hydroxyl group of the ligand. In addition, compound **2** does not interact directly with helix 12 (Fig. 1h) but compound **3** restores the intimate hydrophobic interactions with Val414 and Phe418 on helix 12 (Fig. 1i). However, the restoration of the hydrogen bond network and hydrophobic interactions in the complex with **3** is not complete, which may explain the weak agonist activity of **3**. The differences mentioned above are likely thought to be the source of the agonism of **3** and antagonism of **2**. It should be noted that in the complex of VDR with GEMINI, which is an agonist, the side chain hydroxyl group at C(25) forms hydrogen bonds with the corresponding two histidines and the side chain terminus of the ligand interacts with hydrophobic residues of VDR in a manner similar to that of the complex with **1** [6,7].

We evaluated ligand-dependent recruitment of RXR $\alpha$  and a coactivator peptide, SRC-1, by VDR using a mammalian two-hybrid assay in HEK293 cells. As shown in Fig. 2a and b, compounds **2** and **3** recruited RXR $\alpha$  weakly in a concentration-dependent manner. Fig. 2c shows that compound **2** slightly inhibited RXR $\alpha$  recruitment induced by natural hormone **1**, whereas compound **3** did not. These results demonstrate that both **2** and **3** can heterodimerize with RXR $\alpha$ , albeit weakly. In the recruitment of SRC-1, compound

**Table 1**  
Summary of data collection statistics and refinement.

Data set	rVDR-LBDdel + 3 + Peptide
X-ray source	KEK-PF BL-6A
Wavelength [Å]	0.97800
Space group	C2
Unit cell dimensions [Å]	$a = 153.45$ , $b = 43.39$ , $c = 41.99$
[°]	$\alpha = 90.00$ , $\beta = 95.34$ , $\gamma = 90.00$
Resolution range [Å] <sup>a</sup>	50.00–2.00 (2.07–2.00)
Total number of reflections	67380
No. of unique reflections	19085
% completeness <sup>a</sup>	97.5 (88.9)
$R_{\text{merge}}^{\text{a,b}}$	0.064 (0.211)
Refinement statistics	
Resolution range [Å] <sup>a</sup>	50.00–2.00 (2.07–2.00)
$R$ factor ( $R_{\text{free}}/R_{\text{work}}$ ) <sup>a,c</sup>	0.264 (0.348)/0.216 (0.339)

<sup>a</sup> Values in parentheses are for the highest-resolution shell.

<sup>b</sup>  $R_{\text{merge}} = \sum |(I_{hkl} - \langle I_{hkl} \rangle)| / (\sum I_{hkl})$ , where  $\langle I_{hkl} \rangle$  is the mean intensity of all reflections equivalent to reflection  $hkl$ .

<sup>c</sup>  $R_{\text{free}} (R_{\text{free}}) = \sum ||F_{\text{obs}}| - |F_{\text{calc}}|| / \sum |F_{\text{obs}}|$ , where 10% of randomly selected data were used for  $R_{\text{free}}$ .

Download English Version:

<https://daneshyari.com/en/article/1992419>

Download Persian Version:

<https://daneshyari.com/article/1992419>

[Daneshyari.com](https://daneshyari.com)